Hiroki Ishihara1, Tsunenori Kondo2, Kazuhiko Yoshida1, Kenji Omae3, Toshio Takagi1, Junpei Iizuka1, Kazunari Tanabe1. 1. Department of Urology, Kidney Center, Tokyo Women's Medical University, Tokyo, Japan. 2. Department of Urology, Kidney Center, Tokyo Women's Medical University, Tokyo, Japan; Department of Urology, Tokyo Women's Medical University Medical Center East, Tokyo, Japan. Electronic address: tkondo@twmu.ac.jp. 3. Department of Urology, Kidney Center, Tokyo Women's Medical University, Tokyo, Japan; Department of Healthcare Epidemiology, Kyoto University Graduate School of Medicine/School of Public Health, Kyoto, Japan; Center for Innovative Research for Communities and Clinical Excellence, Fukushima Medical University, Fukushima City, Japan.
Abstract
BACKGROUND: The usefulness of the aspartate transaminase (AST)/alanine transaminase (ALT) ratio (De Ritis ratio) as a predictive biomarker for patients with metastatic renal cell carcinoma (mRCC) undergoing cytoreductive nephrectomy (CN) remains unclear. PATIENTS AND METHODS: The data from 118 patients were retrospectively evaluated. The endpoints were cancer-specific survival (CSS) and overall survival (OS) after CN. We compared these according to the AST/ALT ratio before and after 1:1 propensity score matching. The independent predictors for CSS and OS were also analyzed. RESULTS: The area under the receiver operating characteristic curve was 0.603. The maximum Youden index indicated that the cutoff value for the AST/ALT ratio was 1.24. Before matching, a high AST/ALT ratio was significantly associated with inferior CSS and OS (P < .05 for all). After matching, 34 patients each were allocated to the high and low AST/ALT ratio groups. In the matched cohort, CSS and OS tended to be lower in the high AST/ALT ratio group, although the results were not statistically significant (median CSS, 18.4 months vs. not reached, P = .121; OS, 18.4 months vs. not reached, P = .0957). Furthermore, multivariate analyses revealed that the AST/ALT ratio was an independent predictor for CSS and OS (CSS hazard ratio, 2.17, P = .0472; OS hazard ratio, 2.30, P = .0258). CONCLUSION: The preoperative AST/ALT ratio can be an effective predictive biomarker for CSS and OS in patients with mRCC.
BACKGROUND: The usefulness of the aspartate transaminase (AST)/alanine transaminase (ALT) ratio (De Ritis ratio) as a predictive biomarker for patients with metastatic renal cell carcinoma (mRCC) undergoing cytoreductive nephrectomy (CN) remains unclear. PATIENTS AND METHODS: The data from 118 patients were retrospectively evaluated. The endpoints were cancer-specific survival (CSS) and overall survival (OS) after CN. We compared these according to the AST/ALT ratio before and after 1:1 propensity score matching. The independent predictors for CSS and OS were also analyzed. RESULTS: The area under the receiver operating characteristic curve was 0.603. The maximum Youden index indicated that the cutoff value for the AST/ALT ratio was 1.24. Before matching, a high AST/ALT ratio was significantly associated with inferior CSS and OS (P < .05 for all). After matching, 34 patients each were allocated to the high and low AST/ALT ratio groups. In the matched cohort, CSS and OS tended to be lower in the high AST/ALT ratio group, although the results were not statistically significant (median CSS, 18.4 months vs. not reached, P = .121; OS, 18.4 months vs. not reached, P = .0957). Furthermore, multivariate analyses revealed that the AST/ALT ratio was an independent predictor for CSS and OS (CSS hazard ratio, 2.17, P = .0472; OS hazard ratio, 2.30, P = .0258). CONCLUSION: The preoperative AST/ALT ratio can be an effective predictive biomarker for CSS and OS in patients with mRCC.
Authors: Ross J Mason; Lori Wood; Anil Kapoor; Naveen Basappa; George Bjarnason; Stephen A Boorjian; Rodney H Breau; Ilias Cagiannos; Michael A S Jewett; Pierre I Karakiewicz; Wassim Kassouf; Christian Kollmannsberger; Aly-Khan A Lalani; Jean-Baptiste Lattouf; Luke T Lavallée; Stephen Pautler; Nicholas Power; Patrick Richard; Alan So; Simon Tanguay; Ricardo A Rendon Journal: Can Urol Assoc J Date: 2019-06 Impact factor: 1.862
Authors: Jakob Michael Riedl; Florian Posch; Gerald Prager; Wolfgang Eisterer; Leopold Oehler; Thamer Sliwa; Klaus Wilthoner; Andreas Petzer; Petra Pichler; Eva Hubmann; Thomas Winder; Sonja Burgstaller; Markus Korger; Johannes Andel; Richard Greil; Hans-Joerg Neumann; Martin Pecherstorfer; Kathrin Philipp-Abbrederis; Angela Djanani; Birgit Gruenberger; Friedrich Laengle; Ewald Wöll; Armin Gerger Journal: Ther Adv Med Oncol Date: 2020-04-10 Impact factor: 8.168
Authors: Florian Janisch; Thomas Klotzbücher; Roland Dahlem; Michael Rink; Phillip Marks; Christina Kienapfel; Christian P Meyer; Hang Yu; Constantin Fühner; Tobias Hillemacher; Keiichiro Mori; Hadi Mostafei; Shahrokh F Shariat; Margit Fisch Journal: World J Urol Date: 2021-03-01 Impact factor: 4.226